Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vulvar intraepithelial neoplasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Vulvar intraepithelial neoplasia. Displaying page 1 of 1.
    EudraCT Number: 2012-002052-17 Sponsor Protocol Number: PITVIN Start Date*: 2012-09-21
    Sponsor Name:Medizinische Universität Graz, Univ. Frauenklinik, Abteilung für Gynäkologie
    Full Title: Primary Imiquimod Treatment versus Surgery for Vulvar Intraepithelial Neoplasia: A Prospective Randomized Controlled Trial
    Medical condition: Vulvar intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004872 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006761-32 Sponsor Protocol Number: A 091152 Start Date*: 2008-04-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: Vulval intraepithelial neoplasia: immune responses to human papillpmavirus.
    Medical condition: Vulval intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005230-37 Sponsor Protocol Number: HPV01/01 Start Date*: 2008-04-02
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV1...
    Medical condition: Adult female patients, with histological evidence of Vulvar intraepithelial neoplasia (VIN) grade III lesions of the squamous cell type, positive for HPV (Human Papilloma Virus)16.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2015-002724-16 Sponsor Protocol Number: CLS001-CO-PR-010;CHDR1508 Start Date*: 2015-10-15
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double-blind, parallel-group study to assess the pharmacodynamics, safety/tolerability and efficacy of topical omiganan in patients with usual type vulvar intraepithelial neo...
    Medical condition: Patients with usual type vulvar intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038604 - Reproductive system and breast disorders 10054932 Vulvar dysplasia PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002247-23 Sponsor Protocol Number: MITOCERV4 Start Date*: 2020-01-29
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Single arm phase II study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesions
    Medical condition: Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10054932 Vulvar dysplasia PT
    20.0 10038604 - Reproductive system and breast disorders 10008263 Cervical dysplasia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-008251-42 Sponsor Protocol Number: 26014 Start Date*: 2009-09-07
    Sponsor Name:Erasmus MC
    Full Title: Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN
    Medical condition: In this trial, the efficacy of Gardasil combined with imiquimod in women with usual type Vulvar Intraepithelial Neoplasia is investigated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047778 Vulvar cancer in situ LLT
    9.1 10066416 Vulvovaginal human papilloma virus infection LLT
    9.1 10046859 Vaccination LLT
    9.1 10062059 Histology abnormal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003134-13 Sponsor Protocol Number: A551109 Start Date*: 2012-02-13
    Sponsor Name:Erasmus MC
    Full Title: 5-Aminolevulinic Acid PhotoDynamic Therapy for the treatment of premalignant disorders of the vulva.
    Medical condition: Premalignant vulvar disorders (usual type Vulvar Intraepithelial Neoplasia)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062135 Vulval neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003107-19 Sponsor Protocol Number: 13-0288 Start Date*: 2014-04-28
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Sandwell and West Birmingham Hospitals NHS Trust
    Full Title: Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia
    Medical condition: Vulval intraepithelial neoplasia (VIN)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10057313 Vulval intraepithelial neoplasia grade III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004327-11 Sponsor Protocol Number: SPON 245-06 Start Date*: 2008-10-23
    Sponsor Name:Cardiff University
    Full Title: A randomised phase II multi-centre trial of topical treatment in women with vulval intraepithelial neoplasia
    Medical condition: Vulval Intraepithelial Neoplasia grade 3 (VIN 3)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057313 Vulval intraepithelial neoplasia grade III LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004893-42 Sponsor Protocol Number: 1.0 Start Date*: 2008-10-15
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für dermatologie
    Full Title:
    Medical condition: Condyloma accuminata, Vulvar Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047762 Vulval neoplasms benign HLT
    9.1 10010291 Condyloma acuminatum LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005339-42 Sponsor Protocol Number: N16HPV Start Date*: 2016-08-30
    Sponsor Name:NKI-AVL
    Full Title: Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II study
    Medical condition: HPV16+ usual type vulvar intraepithelial neoplasia (uVIN)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002035-26 Sponsor Protocol Number: 115411 Start Date*: 2011-10-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10033723 Papilloma viral infection NOS LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    14.0 10038604 - Reproductive system and breast disorders 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002932-42 Sponsor Protocol Number: V501-110-01 Start Date*: 2016-12-14
    Sponsor Name:MSD K.K., a subsidiary of Merck & Co., Inc
    Full Title: A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 ...
    Medical condition: Human Papillomavirus infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 11:34:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA